Jansen, M. P. http://orcid.org/0000-0003-1929-6350
Hodgins, D.
Mastbergen, S. C.
Kloppenburg, M.
Blanco, F. J.
Haugen, I. K.
Berenbaum, F.
Eckstein, F.
Roemer, F. W.
Wirth, W.
Funding for this research was provided by:
Innovative Medicines Initiative (115770)
Article History
Received: 13 February 2024
Revised: 20 March 2024
Accepted: 20 March 2024
First Online: 27 March 2024
Declarations
:
: DH: founder and CEO of Dynamic Metrics Ltd, owner of GaitSmart. MK: consulting fees from Abbvie, Pfizer, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis, UCB, all paid to institution. FJB: funding from Gedeon Richter Plc., Bristol-Myers Squibb International Corporation (BMSIC), Sun Pharma Global FZE, Celgene Corporation, Janssen Cilag International N.V, Janssen Research & Development, Viela Bio, Inc., Astrazeneca AB, UCB BIOSCIENCES GMBH, UCB BIOPHARMA SPRL, AbbVie Deutschland GmbH & Co.KG, Merck KGaA, Amgen, Inc., Novartis Farmacéutica, S.A., Boehringer Ingelheim España, S.A, CSL Behring, LLC, Glaxosmithkline Research & Development Limited, Pfizer Inc, Lilly S.A., Corbus Pharmaceuticals Inc., Biohope Scientific Solutions for Human Health S.L., Centrexion Therapeutics Corp., Sanofi, TEDEC-MEIJI FARMA S.A., KiniksaPharmaceuticals, Ltd. Grunenthal. IKH: Research grant (ADVANCE) from Pfizer (payment to institution) and consulting fees from Novartis, Grünenthal and GSK, outside of the submitted work. FB: Institutional grants from TRB Chemedica and Pfizer. Consulting fees from AstraZeneca, Boehringer Ingelheim, Heel, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, MerckSerono, MSD, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, 4P Pharma. Honoraria for lectures from Pfizer, Eli Lilly, Viatris. Payment for expert testimony from Pfizer and Eli Lilly. Travel support from Nordic Pharma, Pfizer, Eli Lilly, Novartis. Stock owner and CMO of 4Moving Biotech. FE: CEO and shareholder of Chondrometrics GmbH, received personal fees from TrialSpark, 4P Pharma, Norvartis, Servier, Galapagos and Merck and grants from PMU, BMBF, EU, NIH, FNIH, Merck, Galapagos NV, Novartis, TissueGene, CALIBR, ICM, Bioclinica/Clario, Universities of Erlangen Sydney, Basel Western Ontario, Stanford and Utrecht. FWR: shareholder of Boston Imaging Core Lab (BICL), LLC and consultant to Calibr and Grünenthal. WW: Employee and shareholder of Chondrometrics GmbH and consulting fees from Galapagos NV. The other authors have nothing to disclose.